Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

The Euro 2020 is set to begin June 11 with the Group Stage and run through July 11. The games will be aired on ESPN and EPSN+, both units of&nbsp;Walt Disney Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>).
Ahead of the quadrennial soccer tournament featuring the top teams in Europe, Benzinga is providing group betting previews. Group F Betting Odds from Draftkings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). are:
<ul>
<li>France +143 to win Group F, -250 to finish in top two</li>
<li>Germany +175 to win Group F, -200 to finish in top two</li>
<li>Portugal +290 to win Group F, -165 to finish in top two</li>
<li>Hungary +4000 to win Group F, +850 to finish in top two</li>
</ul>
There are many betting options for soccer games which include betting on the winner, a tie, a team to win or tie, over/under, correct score, both teams to score and the winning margin.
For this betting preview, we will be looking at who is likely to win Group E and finish second as the top two teams will advance past the group stage.
The group of death is here with Group F featuring four teams from the top 40 rankings by FIFA, including three ranked in the top 12.
France (FIFA rank: 2) is favored to win the group but also offers decent betting odds at +143. The team went 8-1-1 in qualifying with Turkey being the team it couldn&rsquo;t get past with a loss and a draw. The team is the favorite to win the entire Euro 2020.
Germany (FIFA rank: 12) won its group going 7-0-1 in a competitive qualifying group with the Netherlands. The team posted a 3-2 win over the Netherlands and a 4-2 loss. The team had 30 goals scored and 7 goals allowed in qualifying.
If you take out the two matches against the Netherlands, Germany allowed only one goal and had five clean sheets in the other six matches.
Portugal (FIFA rank: 5) finished second to Ukraine in its qualifying group with a 5-2-1 record. The team led the group with a goal differential of 16 and saw 11 goals scored by Cristiano Ronaldo. The team had some questionable matches including a loss and draw with Ukraine and a 1-1 draw with Serbia.
The unfortunate team in the group of death is Hungary (FIFA rank: 37) which&nbsp;will not only find itself facing teams desperate for wins in the group but also looking to dominate goals scored and goal differentials for possible tie breaks.
The team finished 4-0-4 in qualifying, scoring only 8 goals in the matches.
Group F Picks: Bettors may want to consider staying away from&nbsp;group stage betting&nbsp;and place wagers on the top three teams for further on in the Euro.
The nice thing is that two teams will advance and a third could as well with the formatting of the tournament (top four third-place teams move on).
Since October, Germany has lost to North Macedonia and lost to Spain 6-0. This team could be seeking a chance to prove it is still a world power and could be the pick to win the group.
I think the group goes Germany, France, Portugal, but that could be a complete guess at this point.
(Image by&nbsp;<a href="https://pixabay.com/users/pixel2013-2364555/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3471402">S. Hermann &amp; F. Richter</a>&nbsp;from&nbsp;<a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3471402">Pixabay</a>)

Sports

General

DKNG

Euro 2020 Group F Betting Preview And Picks

Boss Tweed, the notorious 19th-century New York City political chieftain, once remarked,&nbsp;&ldquo;The way to have power is to take it.&rdquo;
Tweed&rsquo;s philosophy appears to have survived well into the 21st century, at least according to Jan Eeckhout, author of the new book &ldquo;The Profit Paradox: How Thriving Firms Threaten the Future of Work.&rdquo;
In his book, Eeckhout details how a relatively small number of companies have created an off-kilter environment over the past four decades in which&nbsp;they have consolidated economic controls to a point where they can exist without fear of either competition or government regulation. As a result of this situation, workforce wages have mostly stagnated and prices on consumer and industrial goods are in constant ascension.
Eeckhout, who is the ICREA Research Professor at Pompeu Fabra University in Barcelona and previously taught at the University of Pennsylvania, University College London, Princeton University and New York University, spoke with Benzinga about &ldquo;The Profit Paradox&rdquo; and the state of global macroeconomy.
Benzinga: How did you come about with the thesis for your work?
JE: The thesis is based on facts, and we see two things. First of all, with the new fast technological change that&#39;s going on, we see that those highly productive firms &mdash;&nbsp;these very big innovators &mdash;&nbsp;have become very profitable, which is a good thing because innovation is a good thing. That&#39;s the driver of the economy, that&#39;s how we get progress and growth.
At the same time, this past ecological change has also led to a lopsidedness within the industries, because an Amazon&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) or a Facebook&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fb#NASDAQ">FB</a>) is so productive and is so much better than anyone else that they actually grab the entire market.
Still, couldn&rsquo;t an argument be made that these companies are giving the public what it wants?
JE: I&#39;m the first one who loves Amazon, because I get a lot of stuff at a low price and it&#39;s very convenient. But the reason why they can do it is because our central tenets of competition don&#39;t work.
What happens is that the first innovator in a market is the winner &mdash;&nbsp;it has competed heavily to get there. But once they&#39;re there, there&#39;s a huge barrier for other firms to come in to compete in that market.
Let me give you an example. In the &#39;90s,&nbsp;Yahoo tried&nbsp;to get into the online auction market but never got a hold because eBay (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) had 90% to 95% of the auction market.
But if you look at what happened in Japan, Yahoo Auctions was first and eBay has less than 5% of the market share &mdash;&nbsp;they can&#39;t get it. So, it&#39;s not that eBay is superior to Yahoo, it was that eBay was first.
See Also: <a href="https://www.youtube.com/watch?v=YOVpYSmmPwA">After Hours with Ryan Rozbiani: Will Inflation Crash The Market?</a>
But doesn&rsquo;t each generation bring a new wave of innovators creating different ways to change the economy?
JE: While the innovation was very valuable in the &#39;90s, 30 years on this innovation has stopped happening and the only thing that we see now is basically barriers to entry. The start-up rate is half what it was in the &#39;90s.
When people try to start up a new company, they face these huge giants and two things can happen with the giants: either they buy you, either at a price that&#39;s very low or in a killer acquisition where they buy and they just kill you off immediately, or they let you do what you do and they just copy your technology.
The COVID-19 pandemic created chaos on all economies around the world. Did this period of tumult change the landscape in any way for the better?
JE: From looking at the Dow Jones, the profitability of the largest firms has gone up even more &mdash;&nbsp;we know the Dow Jones is close to 35,000 and the growth since the pandemic has been enormous. This seems to indicate that what the pandemic has is to create innovation, and a lot of firms had to just be doing business in a different way. For example, you and I are talking over Zoom (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>), and many of our meetings would have been very different a year and a half ago.
But a lot of the smaller companies had to close down, either declaring bankruptcy or just simply leaving the market.
Overall, we see that large firms&rsquo; profitability had gone up even further than it was before the pandemic, and I think that&#39;s a sign that these firms have been beneficiaries of the pandemic.
What is the role of the government in addressing this situation?
JE: What I suggest in terms of government intervention &mdash;&nbsp;and it might sound like an oxymoron &mdash;&nbsp;but the government should ensure more competition. If a market has barriers to entry, anti-trust regulations should ensure more competition rather than less competition.
There&#39;s an important distinction to be made. There is a role for anti-trust legislation, but my view is they don&#39;t have to split up firms. There&#39;s no kind of gain in splitting up Amazon. The reason why Amazon is so efficient and cost-effective is because they&#39;re so large, so let&#39;s keep the size. But the government can do other things to induce competition.
Speaking of competition, how can the economy that you describe in your book compete against China?
JE: China is going through a transition from a planned economy to a market economy, and we see in the data that China is the one country where the degree of concentration is actually going down.
They still have a lot of state-owned enterprises which are massive, but these government companies are not very efficient and are now facing competition from many of the private companies in China.
As a result of that, there is a degree of competitiveness that&#39;s increasing because they&#39;re weeding out these massive state-owned enterprises. So, China is somewhat different from the rest of the world.
How does that work in terms of the competition? Ultimately, for the customer, it doesn&#39;t matter whether your company is Apple&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) or Alibaba (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>). I have an American phone in my pocket, and you probably drink a Belgian beer in the United States. If you read a book by Penguin, it&#39;s owned by a German company, and if you buy through Alibaba, it&#39;s a Chinese company.
But ultimately, it&#39;s the customer&#39;s location that matters because that is where the market power is,&nbsp;especially with the top 100 global firms, because that is exactly the kind of the issue of what&#39;s going on. It&#39;s a global phenomenon.
&ldquo;The Profit Paradox: How Thriving Firms Threaten the Future of Work,&rdquo; published by Princeton University Press.
(Photo of Jan Eekhout courtesy of ICREA.)

Economics

Exclusives

Interview

AAPL

AMZN

BABA

EBAY

EXCLUSIVE: Jan Eeckhout's 'The Profit Paradox' Details How Lack Of Competition Warps Economies

On Saturday, Barbora Krejcikova won just her second WTA women&rsquo;s singles title ever winning the 2021 Women&rsquo;s French Open.
Krejcikova entered the tournament with low odds to win the title, which could have turned in a nice profit for bettors.
What Happened: Krejcikova, who entered the French Open unseeded, beat 31st seeded Anastasia Pavlyuchenkova 6-1, 2-6 and 6-4 in three sets to win the 2021 French Open.
The match was Krejcikova&rsquo;s second singles tournament win and came in only the fifth major tournament the 25-year-old took part in.
Krejcikova is the third unseeded women&rsquo;s French Open winner since 2017, after a stretch of 1968 to 2016 that saw only seeded winners.
Related Link: <a href="https://www.benzinga.com/news/21/06/21369727/corporate-sponsors-back-naomi-osaka-on-her-french-open-withdrawal">Corporate Sponsors Back Naomi Osaka On Her French Open Withdrawal</a>
Betting Odds: Krejcikova was a slight favorite at -129 to beat Pavlyuchenkova (+108) entering Saturday&rsquo;s match, according to DraftKings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). The over/under hit the over (-113) of 21.5 games played.
Entering the 2021 French Open, Krejcikova had odds of +8000 (80/1) to win the title.
A $1,000 bet on Krejcikova to win the 2021 Women&rsquo;s French Open paid out a profit of $80,000 for anyone willing to place a bet on the unseeded tennis player from the Czech Republic.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/QkzmPG_tTFY" width="560"></iframe>

Here's The Huge Payout On A $1,000 Bet For Barbora Krejcikova Women's French Open Win

<a href="https://www.timesofisrael.com/liveblog-june-13-2021/" title="https://www.timesofisrael.com/liveblog-june-13-2021/">https://www.timesofisrael.com/liveblog-june-13-2021/</a>

News

Politics

iShares MSCI Israel Capped Investable Market Index Fund

Naftali Bennett of the Right-wing Yamina Party Was Sworn in Sunday as Israel's New Prime Minister, Replacing Benjamin Netanyahu After 12 Years in Power

<a href="https://twitter.com/elonmusk/status/1404132183254523905?s=20" title="https://twitter.com/elonmusk/status/1404132183254523905?s=20">https://twitter.com/elonmusk/status/1404132183254523905?s=20</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers & Shakers

Management

Markets

BTBT

MARA

MSTR

RIOT

TSLA

Elon Musk Tweeted: ...Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market.  When there's confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions.

<ul>
<li>ViacomCBS Inc&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viac#NASDAQ">VIAC</a>) Paramount Pictures film&nbsp;&ldquo;A Quiet Place 2&rdquo; has surpassed $100 million in U.S. ticket sales,&nbsp;<a href="https://variety.com/2021/film/news/a-quiet-place-2-box-office-milestone-pandemic-1234995367/" target="_blank">Variety</a>&nbsp;reports.&nbsp;&nbsp;</li>
<li>The film did $80 million at the international box office and $108 million at the domestic box office through the weekend.&nbsp;</li>
<li>&ldquo;A Quiet Place 2&rdquo; is the first pandemic-era film to play exclusively in theaters at&nbsp;AMC Entertainment Holdings Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>),&nbsp;Cinemark Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnk#NYSE">CNK</a>), and Regal cinemas.</li>
<li>The film debuted with a pandemic record of $48 million and made $58 million in its first five days of release. It was released over Memorial Day.&nbsp;</li>
<li>The first series of the film made $340 million globally and&nbsp;cost $17 million to produce. &ldquo;A Quiet Place 2&rdquo; was made at a budget of $61 million.</li>
<li>AT&amp;T Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)&nbsp;subsidiary Warner Bros. and Legendary Pictures Productions LLC&rsquo;s &ldquo;Godzilla vs. Kong&rdquo;&nbsp;is also reportedly heading toward&nbsp;the milestone in the next few days. The film&rsquo;s North American total was at $99.4 million.&nbsp;</li>
<li>The movie won&rsquo;t be available in the home via Paramount+ until 45 days after it first hit the big screen.</li>
<li>The last film to earn north of $100 million in North America was Paramount&rsquo;s &ldquo;Sonic the Hedgehog, &quot;&nbsp;released in February 2021.</li>
</ul>
Picture courtesy: Official Facebook page of the movie &ldquo;A Quiet Place 2&rdquo;

VIAC

'A Quiet Place 2' Breaks Pandemic-Era Box Office Records, Surpassing $100M

This article by Johnny Green was originally published on<a href="https://cannatechtoday.com/">&nbsp;Cannabis &amp; Tech Today</a>, and appears here with permission.
Historically, cannabis was portrayed as the scourge of humankind. Films like &lsquo;<a href="https://cannatechtoday.com/reefer-madness/">Reefer Madness</a>&rsquo;&nbsp;were coupled with other forms of propaganda and spread throughout the world.
That propaganda had one goal &ndash; to demonize cannabis users. Cannabis consumers were portrayed in horrific ways that weren&rsquo;t based in fact in an attempt to convince society that the &lsquo;harms&rsquo; of cannabis were significant and factual.
The fact of the matter is that cannabis is much safer than many other legal substances, including and especially alcohol.
One&nbsp;<a href="https://www.newsweek.com/cannabis-more-100-times-safer-alcohol-study-finds-309035">study</a>&nbsp;found that cannabis was 114 times safer than alcohol. A more recent study found that cannabis may actually be able to reduce alcohol cravings.
<h3>CBD and Alcohol Consumption Study</h3>
The&nbsp;<a href="https://cannatechtoday.com/canadian-medical-cannabis-patients-report-reductions-in-alcohol-use/">cannabis</a>&nbsp;plant is composed of dozens of cannabinoids, with THC and CBD being the two most popular cannabinoids.
CBD&rsquo;s popularity has exploded in recent years, and for good reason. CBD is associated with a number of wellness benefits, including a potential reduction in alcohol consumption.
Alcohol abuse is a global issue, with over 100 million people suffering from alcohol use disorder worldwide. Roughly 3 million people die annually across the globe due to alcohol use.
A team of researchers recently published results of a&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/33764086/">study</a>&nbsp;that explored the relationship between CBD use and alcohol use.
&ldquo;The present study lends preliminary support to the notion that plant-based CBD may be associated with decreased alcohol consumption among regular cannabis users and suggests that it may be feasible for regular cannabis users to switch to a higher CBD, lower THC content cannabis strain for the purposes of reducing their alcohol intake,&rdquo; the study&rsquo;s authors concluded.
<h3>Making the Safer Choice</h3>
If you feel that you consume too much alcohol and are having a hard time cutting back or eliminating alcohol from your life, you should definitely give CBD a try.
By virtually every measure CBD is safe, and as the study linked above demonstrates, it&rsquo;s effective for a lot of people when it comes to reducing alcohol consumption.
Unlike THC (and&nbsp;<a href="https://cannatechtoday.com/public_policy_alcohol_cannabis/">alcohol</a>), CBD is not associated with generating euphoric effects, which is obviously important for people that want to refrain from feeling intoxicated.
Thanks to cannabis reform victories in a laundry list of countries, CBD is now legal in many different forms and is widely available.
Read the original article on&nbsp;<a href="https://cannatechtoday.com/cbd-lower-alcohol-consumption/">Cannabis &amp; Tech Today</a>.
<a href="https://benzinga.com/cannabis/" rel="noopener noreferrer" target="_blank">Benzinga</a>&#39;s Related Links:&nbsp;
<ul>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/20/10/17746133/why-the-drinks-market-will-be-the-next-big-sector-in-cannabis-and-cbd&amp;sa=U&amp;ved=2ahUKEwjh0YOjsPfwAhVQErkGHeitBP4QFjACegQIABAC&amp;usg=AOvVaw0XQkjrPZ7Zcp0J0TD7zLFF" target="_blank">Why The Drinks Market Will Be The Next Big Sector In Cannabis</a></li>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/20/05/16057289/cbd-beer-the-bar-has-been-set-high-but-like-just-a-body-high&amp;sa=U&amp;ved=2ahUKEwjh0YOjsPfwAhVQErkGHeitBP4QFjAEegQIARAC&amp;usg=AOvVaw0NtmSPYK4CxRAz_2a1I7U1" target="_blank">CBD&nbsp;Beer: The Bar Has Been Set High, But Like, Just A Body High</a></li>
<li>M&aacute;s de&nbsp;<a href="https://elplanteo.com/author/cannabis-and-tech-today/">Cannabis &amp; Tech Today</a>&nbsp;en espa&ntilde;ol en El Planteo</li>
</ul>

Cannabis

Study Finds CBD Associated With Lower Alcohol Consumption

This article by Johnny Green was originally published on<a href="https://cannatechtoday.com/">&nbsp;Cannabis &amp; Tech Today</a>, and appears here with permission.
Currently, there are no fully legal adult-use cannabis countries in Europe, but Luxembourg is moving forward. The only two countries that have legalized cannabis for adult use are Uruguay and Canada.
With that being said, there are already countries in&nbsp;<a href="https://cannatechtoday.com/low-dose-cannabis-gains-in-popularity-in-europe/">Europe</a>&nbsp;that are quasi-legal, such as in Switzerland where low-THC cannabis is bought and sold legally.
In Italy, the Supreme Court ruled previously that home cultivation is legal, and while lawmakers are still trying to sort things out, there are now some legal protections in place for consumers.
Several countries are exploring legalization, and in some cases even launching limited pilot programs such as in the Netherlands, however, one country may be on the fastest path to full legalization in Europe.
<h3>Luxembourg Takes Another Step Forward</h3>
Luxembourg may not be the first country that people think of when it comes to the debate of which country will be the first to fully legalize in Europe.
After all, other countries like the Netherlands are typically much higher on the prediction scale given their longer history with cannabis and public policy.
However, Luxembourg might have more momentum than any other country in&nbsp;<a href="https://cannatechtoday.com/the-european-hemp-scene/">Europe</a>&nbsp;right now regarding legalization.
That was evident recently when lawmakers in Luxembourg&nbsp;<a href="https://twitter.com/ChambreLux/status/1395394796705964033">adopted a motion</a>&nbsp;calling for the development of legal cannabis regulations.
<h4>Will They Beat Other European Countries to Legalization?</h4>
Ultimately, only time will tell if Luxembourg becomes the first to legalize in&nbsp;<a href="https://cannatechtoday.com/report-uk-is-europes-largest-producer-exporter-of-legalized-cannabis/">Europe</a>.&nbsp;
Last summer officials in Luxembourg announced the desire to legalize cannabis for adult-use within two years.
The one year anniversary of that announcement is coming up soon, and with lawmakers calling for draft regulations, things are looking good.
Yet, as the push for legalization in Mexico has demonstrated in recent years, momentum can slow down very quickly.
Just as the push for legalization has experienced numerous setbacks in Mexico, the same could happen in Luxembourg if there is disagreement with provisions that eventually surface in the looming draft regulations.&nbsp;
Read the original article on&nbsp;<a href="https://cannatechtoday.com/luxembourg-closer-to-legalization/">Cannabis &amp; Tech Today</a>
<a href="https://benzinga.com/cannabis/" rel="noopener noreferrer" target="_blank">Benzinga</a>&#39;s Related Links:&nbsp;
<ul>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/21/04/20751935/why-2021-should-prove-the-year-of-federal-cannabis-legalization&amp;sa=U&amp;ved=2ahUKEwj5kaeIsvfwAhURDjQIHaMJC34QFjACegQIBBAC&amp;usg=AOvVaw0pPl9L_7Nyttzq_PTwycgl" target="_blank">Why 2021 Should Prove The Year Of Federal Cannabis&nbsp;Legalization</a></li>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/topic/marijuana-legalization&amp;sa=U&amp;ved=2ahUKEwj5kaeIsvfwAhURDjQIHaMJC34QFjADegQIBxAB&amp;usg=AOvVaw29lH9n4HQQPYOkbb2ofhbD" target="_blank">marijuana&nbsp;legalization&nbsp;| Benzinga</a></li>
<li>M&aacute;s de&nbsp;<a href="https://elplanteo.com/author/cannabis-and-tech-today/">Cannabis &amp; Tech Today</a>&nbsp;en espa&ntilde;ol en El Planteo</li>
</ul>

Global

Luxembourg Moves One Step Closer To Cannabis Legalization

The graph displays total transaction consideration for U.S. and Canadian M&amp;A transactions since 2019.&nbsp;
<img src="https://lh4.googleusercontent.com/MCbp3fvZ2peViieQPsXaNc6SJnwXCKT2OnZT8I5CODscH3dNrH1r2jt8fFes9wOukHfXA20lbrarC5NbWu6CvMzmTCAWM4wdIcuFnEPDYQ42EaAF5qGH3O610ElSHYoxEGNtDuBE" style="height:429px; width:624px" />
<ul>
<li>
In the first half of 2019 the U.S and Canada were closely matched with approximately $2.1 billion of total consideration.&nbsp;&nbsp;
</li>
</ul>
<ul>
<li>
From the 2nd half of 2019 through 2020, Canadian M&amp;A ground to a near standstill while U.S. activity remained robust.
</li>
</ul>
<ul>
<li>
The U.S. dominance was supported by large transactions like Curaleaf&rsquo;s $949 million Select deal in Q1:20 and $830 million Grass Roots deal in Q3:20.
</li>
</ul>
<ul>
<li>
In Q1:21, activity in both countries spiked upward. U.S. activity benefitted from an increase in acquisitions of public companies including Liberty Health, Helix TCS, and Bluma Wellness. Canadian activity included a $353 million Canopy Growth divestiture of its ownership in Canopy Rivers.
</li>
</ul>
<ul>
<li>
Activity has accelerated in the second quarter with the recently completed $4.5B Tilray/Aphria megamerger in Canada and the $2.1B Trulieve/Harvest deal announced in the U.S.&nbsp;&nbsp;
</li>
</ul>
<ul>
<li>
Although consolidation among Canadian LPs in pursuit of positive cash flow is likely to continue, we expect the superior growth potential of the U.S. market to keep U.S. targets at the forefront of M&amp;A activity.
</li>
</ul>
The Viridian Capital Chart of the Week highlights key investment, valuation and M&amp;A trends taken from the Viridian Cannabis Deal Tracker.
The Viridian Cannabis Deal Tracker is a proprietary information service that monitors capital raise and M&amp;A activity in the legal cannabis and hemp industry. Each week the Tracker aggregates and analyzed all closed deals and segments each according to key metrics:
<ul>
<li>
Industry Sector (one of 12 sectors, from Cultivation to Brands)
</li>
<li>
Dollar value of the transaction
</li>
<li>
Region in which the deal occurred (country or U.S. state)
</li>
<li>
Status of the company announcing the transaction (Public vs. Private)
</li>
<li>
Deal structure (equity vs. debt)
</li>
<li>
Key deal terms (Pricing and Valuation)
</li>
</ul>
The <a href="https://viridianca.us1.list-manage.com/track/click?u=078ead34a8bbcfd77b0486326&amp;id=c89a19f9ee&amp;e=2699f9b787">Viridian Cannabis Deal Tracker</a> provides the market intelligence that cannabis companies, investors, and acquirers utilize to make informed decisions regarding capital allocation and M&amp;A strategy.
&nbsp;Since its inception in 2015, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,500 capital raises and 1,000 M&amp;A transactions totaling over $50 billion in aggregate value.
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/como-comprar-dogecoin-doge-en-espana/">C&oacute;mo Comprar Dogecoin (DOGE) en Espa&ntilde;a</a></li>
<li><a href="https://elplanteo.com/acciones-de-marihuana/">C&oacute;mo Invertir en Acciones de Marihuana</a></li>
<li><a href="https://elplanteo.com/resena-etoro-2021/">eToro: Opiniones</a></li>
</ul>

Cannabis Industry Chart Of The Week: US Companies Pursue Growth Through M&A While Canada Consolidates

By Ed Donnelly, founder of AmourCBD
CBD, also known as cannabidiol, is the oil found in the stem of hemp plants which has the THC extracted to reach levels below 0.3%.&nbsp; CBD products have become an everyday essential and as travel begins to pick up, many people are unsure if they can bring their favorite CBD products with them.&nbsp; Here are a few things to keep in mind when bringing your CBD products along.
<ol>
<li>
Consider state laws
</li>
</ol>
Hemp&rsquo;s classification changed under the 2018 Farm Bill from being considered a Schedule I drug, meaning it is no longer considered a controlled substance, thus making consumption, production, and transportation across state lines legal 1. In order to even be considered hemp, products have to meet very strict requirements.&nbsp; For one, the THC percentage in the product cannot be higher than 0.3% otherwise it can be considered marijuana which is yet to be legalized on a federal level.&nbsp; When transporting hemp, the product has to be produced lawfully under the 2018 Farm Bill, and the USDA has to have issued approved regulations and procedures within that specific state.&nbsp; Each production plan was submitted individually by states&mdash;additional information pertaining to that can be found <a href="https://www.ams.usda.gov/rules-regulations/hemp/state-and-tribal-plan-review">here</a>.&nbsp;&nbsp;
<h3>TSA Compliant</h3>
While transporting marijuana across state lines is not allowed since it has not been legalized on a federal level, travelers can still bring most cannabis infused products with them, like CBD, as long as they contain under 0.3% THC 2.&nbsp; Like most hygienic products such as makeup and lotions, the TSA requires that any products brought in carry-on luggage do not exceed 3.4 oz and are stored in a resealable, clear 1 qt bag. Anything greater than 3.4 oz has to be stowed away in checked luggage. Additionally, CBD products do not need to be declared at the airport during domestic travel as they are federally legal in the United States.
<h3>Benefits of CBD for travel jitters</h3>
Why would travelers want to bring CBD along?&nbsp; Various studies have shown that CBD can be used to help alleviate symptoms associated with insomnia, anxiety, and some muscle pains 3.&nbsp; Whatever your fear may be, whether a fear of heights, flying in general, or uneasiness during turbulence, consuming CBD products can help significantly when conquering your flight.&nbsp; Not enough legroom or stiff muscles? CBD creams are your friend.&nbsp; If you want to combat jet lag or simply want to rest on a long flight, travelers can also use CBD in place of products like melatonin.
<h3>International Travel Guidelines</h3>
When traveling internationally, CBD regulations can become a bit less straightforward. While it is legal to travel with CBD products containing less than 0.3% THC domestically in the United States, other countries have different laws regarding CBD use. Before bringing CBD products along for international travel, check on the regulations of the country you are traveling to in order to ensure you are abiding by that country&rsquo;s laws. If you are unsure, professionals suggest leaving CBD products at home since many countries have stricter CBD-related drug laws than the United States 4.
<h3>Check for THC in CBD Products</h3>
Be sure to double check the ingredients of your CBD products before travel. As previously stated, CBD products containing less than 0.3% THC are federally legal, but CBD products containing higher doses of THC can vary in legality by state. Especially when traveling to or from a state where marijuana is legal, make sure to check your CBD products for their THC levels.&nbsp;
Keeping rules and regulations in mind when traveling with your CBD must-haves can help ensure a smooth and relaxing trip, especially during a time we need it most.
Ed Donnelly Bio:
Ed Donnelly is a CBD expert and founder of AmourCBD.&nbsp; With over 30 years of experience working as a Burn Center Nurse in New York and then moving on to assume executive roles in medical technology sales companies, Donnelly entered a new chapter in life when he founded AmourCBD.&nbsp; Combining his experience as a businessman and medical professional, Ed is driven to bring high quality, medical grade products to the CBD market.&nbsp;
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/avion-marihuana/">Aviones, Cannabis y Leyes: &iquest;Podemos Viajar con Marihuana?</a></li>
<li><a href="https://elplanteo.com/viajar-en-pareja-como-los-psicodelicos-pueden-fortalecer-tu-relacion/">Viajar en Pareja: C&oacute;mo los Psicod&eacute;licos Pueden Fortalecer tu Relaci&oacute;n</a></li>
<li>Photo by <a href="https://unsplash.com/@darya_tryfanava?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Darya Tryfanava</a> on <a href="https://unsplash.com/s/photos/plane?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a></li>
</ul>

Travel

What To Know Before Traveling With CBD

Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.
The biggest biotech news of the week came in the form of <a href="https://www.benzinga.com/general/biotech/21/06/21455132/biogen-gets-fda-nod-for-controversial-alzheimers-drug-first-treatment-approval-for-the-disease-in"> approval </a> for Biogen Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) Alzheimer&#39;s drug Aduhelm. The approval polarized the scientific community. The stock, which at one point tacked on about 64% on the day of the approval, ended the week up about 40%.
Alexion Pharmaceuticals, Inc.&#39;s(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxn#NASDAQ">ALXN</a>) Ultomiris received label expansion to treat paroxysmal nocturnal hemoglobinuria in children and adolescents.
Among other approvals that came through during the week were label expansion for Vertex Pharmaceuticals Incorporated&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) triple combo cystic fibrosis drug Trikafta and Pfizer Inc.&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) 20-valent pneumococcal conjugate vaccine.
Vertex, however, had a mixed week, as it <a href="https://www.benzinga.com/general/biotech/21/06/21525331/despite-hitting-mid-stage-trial-endpoint-goal-vertex-strikes-out-rare-lung-disease-candidate-stoc"> announced</a>&nbsp;the shelving of a mid-stage study of a drug for a&nbsp;rare, inherited lung disease.
The week also saw a slew of presentations at multiple scientific meetings. The ASCO 2021 that kickstarted on June 4 ended in the first half of the week, and the European Hematology Association Congress commenced in the later half of the week.
Danish biotech Orphazyme A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orph#NASDAQ">ORPH</a>) and Galecto, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glto#NASDAQ">GLTO</a>) had a volatile ride this week amid a lack of any news specific to the companies.
Here are the key catalysts for the unfolding week:
<h3>Health Care Conferences</h3>
<ul>
<li>BIO Digital 2021: June 14-18</li>
<li>The BofA Securities 2021 Napa Biopharma Virtual Conference: June 14-16</li>
<li>Citi European Healthcare Day: June 15-16</li>
<li>The JMP Securities Life Sciences Conference: June 16-17</li>
<li>J.P. Morgan European Healthcare Conference: June 17</li>
<li>Alliance Global Partners Healthcare Symposium Virtual: June 17</li>
<li>H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference: June 17</li>
</ul>
Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21351378/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-limi"> Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates </a>
<h3>PDUFA Dates</h3>
The FDA is likely to announce by Tuesday, June 15&nbsp;its decision on Takeda Pharmaceutical Company Limited&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tak#NYSE">TAK</a>) new drug application for TAK-721 as a treatment option for eosinophilic esophagitis.
Blueprint Medicines Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpmc#NASDAQ">BPMC</a>) has a decision date of Wednesday, June 16 for its supplemental NDA for Ayvakit as a treatment option for advanced systemic mastocytosis.
The FDA is scheduled to rule on Orphazyme&#39;s NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, a rare, progressive, neurodegenerative disease.
The PDUFA date has been set for Thursday, June 17. Arimocolmol was developed by CytRx Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/cytr#OTC">CYTR</a>) and has been licensed to Orphazyme.
Eton Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eton#NASDAQ">ETON</a>) has a decision-by date of Friday, June 18&nbsp;for its NDA for its ready-to-use ephedrine injection to treat low blood pressure.
<h3>Earnings</h3>
Centogene N.V.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntg#NASDAQ">CNTG</a>) (Wednesday)
<h3>IPOs</h3>
IPO Pricing &amp; Listing 
Atai Life Sciences B.V., a clinical-stage biopharma developing treatments for mental health disorders, has commenced a proposed underwritten initial public offering of 14.286 million shares of its common shares. All common shares to be sold in the proposed offering will be sold by Atai. 
The IPO price is expected to be between $13 and $15 per common share. The German pyschedelics company has applied to list its common shares on the Nasdaq under the ticker symbol &quot;ATAI.&quot;
South San Francisco, California-based Lyell Immunopharma, Inc. has filed for offering 25 million shares of its common stock in an IPO. The oncology-focused company that uses T cells to cure solid tumors, expects to price the offering between $16 and $18. It has applied to list its shares on the Nasdaq under the ticker symbol &quot;LYEL.&quot;
Swiss biopharma Molecular Partners AG proposes to offer 3 million ADSs in an IPO, with each ADS representing the right to receive one common share. The company has given an indicative price of $27.14 per ADS, going by the 24.40 Swiss-franc-per-share price at which its Swiss exchange listed shares closed June 8. The biopharma that focuses on infectious disease, oncology and ophthalmology, has applied to list its ADSs on the Nasdaq under the symbol &quot;MOLN.&quot;
Unicycive, a Los Altos, California-based biopharma that focuses on treatment of kidney diseases, has filed to offer $2.635 million shares at an estimated price range of $8.50-$1.50. The company has applied for listing its shares on the Nasdaq under the ticker symbol &quot;UNCY.&quot;
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21516069/with-aduhelm-approval-behind-biogen-5-catalysts-for-investors-to-watch"> With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch </a>

Biotech

Earnings

Penny Stocks

Health Care

Previews

Small Cap

IPOs

Trading Ideas

ALXN

BIIB

BPMC

CNTG

CYTR

ETON

GLTO

ORPH

VRTX

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs

Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spfr#NYSE">SPFR</a>), the blank-check firm that is set to take 3D printing company Velo3D public.
Shares of the company closed down 0.3% to $10 on Friday.&nbsp;
The Ark Autonomous Technology &amp; Robotics ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkq#BATS">ARKQ</a>) bought shares of Jaws Spitfire. Besides ARKQ, the Ark Space Exploration &amp; Innovation ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkx#BATS">ARKX</a>) also holds shares of the blank-check firm, or&nbsp;special purpose acquisition vehicle.
Velo3D is a 3D printer supplier for SpaceX, the space exploration company led by Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk. It expects the deal with Jaws Spitfire to close in the second half of the year and list under the &quot;VLD&quot; ticker on the New York Stock Exchange.
The company, backed by tennis player Serena Williams, was founded by Miami-based investment firm Starwood Capital Group&rsquo;s Barry Sternlicht, which has about $80 billion worth of assets under management.
On a consolidated basis, ARKQ and ARKX together held 3.42 million shares, worth $34.32 million, in Jaws Spitfire.&nbsp;
See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/21/05/21311511/cathie-wood-loads-up-another-292k-in-spacex-partner-velo3ds-spac?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga%2Fbest-of-benzinga+%28The+Best+of+Benzinga%29&amp;utm_content=Google+Feedfetcher" style="text-decoration:none">Cathie Wood Loads Up Another $292K In SpaceX Partner Velo3D&#39;s SPAC</a>
The investment firm&#39;s&nbsp;3D Printing ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/prnt#BATS">PRNT</a>) is dedicated to the 3D printing industry. PRNT has grown about 21.7% so far this year and has 3D Systems Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) as its top holdings among a total of 56 stocks.
The New York-based investment firm also bought 154,453 shares, worth about $29.8 million, in biotech company Vertex Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) on the dip.
Shares of Vertex Pharmaceuticals closed about 11% lower to $193.02 on Friday.&nbsp;
Barclays on Friday <a href="https://www.benzinga.com/analyst-ratings/price-target/21/06/21526917/10-biggest-price-target-changes-for-friday">lowered</a>&nbsp;its&nbsp;Vertex Pharmaceuticals&nbsp;price target from $302 to $285.
Some of the other key Ark Invest sells on Friday included Guardant Health Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gh#NASDAQ">GH</a>) and buys included 908 Devices Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mass#NASDAQ">MASS</a>).&nbsp;
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/NUehKZBLBCQ" width="560"></iframe>

Sector ETFs

Tech

ETFs

ARKQ

ARKX

MASS

PRNT

SPFR

Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip

<ul>
<li>Thrasio, a start-up company that rolls up&nbsp;Amazon.com, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) marketplace brands, is in talks to go public through a merger with the blank check company&nbsp;Churchill Capital V Corp&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccv#NYSE">CCV</a>),&nbsp;<a href="https://www.bloomberg.com/news/articles/2021-06-11/thrasio-is-said-in-talks-to-go-public-via-michael-klein-spac?sref=TBDibEcD">Bloomberg</a>&nbsp;reported,&nbsp;citing people with knowledge of the matter.</li>
<li>No deal has been finalized yet, and the merger could fall apart, the report said.&nbsp;</li>
<li>Thrasio could be valued at $2 billion in the merger. According to people familiar with the subject, the valuation may reach up to $10 billion, the Friday report said.&nbsp;</li>
<li>Former Citigroup Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) rainmaker Michael Klein set&nbsp;up Churchill Capital V.&nbsp;</li>
<li>In January, Thrasio raised $500 million via&nbsp;JPMorgan Chase &amp; Co.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>),&nbsp;Goldman Sachs Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>)&nbsp;and the asset management arm of&nbsp;Royal Bank of Canada&nbsp;(TSE: RY).</li>
<li>The company has also raised $260 million in C funding led by Advent International.</li>
<li>Thrasio aims to capitalize on Amazon&rsquo;s e-commerce dominance by acquiring new sellers on its third-party marketplace.</li>
<li>In December 2020, Churchill Capital V raised $500 million in its initial public offering.</li>
</ul>

Emerging Market ETFs

Startups

Thrasio In Talks To Merge With SPAC Churchill Capital V: Report

-Reuters
<a href="https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/" title="https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/">https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/</a>

Rumors

Legal

Washington Prime Group to File Bankruptcy as Soon as this Week

Futures

Commodities

Asset Sales

RDS.A

RDS.B

Reuters Reports Royal Dutch Shell Preparing Potential Sale of Its U.S. Permian Basin Assets Which are Expected to Fetch $10B+

LeBron James is switching his jersey next season from number 23 to number 6. Here&rsquo;s a look at how James has performed stat-wise and sports-betting-wise for both jersey numbers.
What Happened: LeBron James spent the last three seasons with the Los Angeles Lakers and 11 prior seasons with the Cleveland Cavaliers with the jersey number 23. James will be <a href="https://www.benzinga.com/news/21/06/21481507/nikes-new-lebron-19-shoes-to-debut-in-space-jam-2">wearing </a>jersey #6 for the Tune Squad in &ldquo;Space Jam: A New Legacy,&rdquo; a new film from AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>).
In his four seasons with the Miami Heat, James wore jersey number 6. This is how James has performed stat-wise based on his teams:
<ul>
<li>Cleveland Cavaliers: 27.2 points, 7.3 rebounds, 7.3 assists</li>
<li>Miami Heat: 26.9 points, 7.6 rebounds, 6.7 assists</li>
<li>Los Angeles Lakers: 25.9 points, 8.0 rebounds, 8.9 assists</li>
<li>Career: 27.0 points, 7.4 rebounds, 7.4 assists</li>
</ul>
In his four seasons with the Heat and jersey #6, James posted these stat lines:
<ul>
<li>2010-2011: 26.7 points, 7.5 rebounds, 7.0 assists</li>
<li>2011-2012: 27.1 points, 7.9 rebounds, 7.2 assists</li>
<li>2012-2013: 26.8 points, 8.0 rebounds, 7.3 assists</li>
<li>2013-2014: 27.1 points, 6.9 rebounds, 6.3 assists</li>
</ul>
Here&rsquo;s how James has performed for bettors with both jersey numbers, according to <a href="https://twitter.com/ActionNetworkHQ/status/1402990684932505602">Action Network</a>.
<ul>
<li>#6 Straight Up: 274-107, 71.9%</li>
<li>#6 Against the Spread: 196-182-3, 51.9%</li>
<li>#23 Straight Up: 770-424, 64.5%</li>
<li>#23 Against the Spread: 597-577-20, 50.9%</li>
</ul>
The results above show that James performs better for bettors on average when he is wearing jersey number 6.
Related Link: <a href="https://www.benzinga.com/general/sports/21/06/21438793/nba-finals-wont-feature-one-of-these-7-players-for-first-time-since-1990">NBA Finals Won&rsquo;t Feature One Of These 7 Players For First Time Since 1990</a>
Disappointing Season?: Heading into 2021, the Lakers were the favorite to win the NBA Championship with odds of +270 from DraftKings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). Heading into the NBA Playoffs, the Lakers <a href="https://dknation.draftkings.com/2021/5/17/22436125/nba-playoffs-2021-championship-odds-to-win-nets-lakers-bucks-sleepers-jazz-suns-favorites-warriors">had </a>the second-best odds to win&nbsp;at odds of +400 behind the Brooklyn Nets at +250.
For the <a href="https://www.benzinga.com/general/sports/21/06/21415766/will-lebron-lose-his-perfect-14-0-record-in-the-first-round-suns-lakers-game-6-betting-preview-pic">first time</a> in his NBA career, James was knocked out in the first round, after going 14-0 in his prior NBA Playoffs history.
James <a href="https://www.nba.com/news/nikola-jokic-wins-2020-21-kia-nba-most-valuable-player-award">had </a>odds to win the NBA MVP of +700 to start the season, raking slightly behind favorites Giannis Antetokounmpo and Luka Doncic at +600. James had his odds drop down to +175 later on in the season.
James finished&nbsp;13th in the NBA MVP voting by 100 panelists and a vote from the fans. James finished with one fifth-place vote, good for one weighted point overall. Nikola Jokic <a href="https://www.benzinga.com/general/sports/21/06/21492063/heres-how-much-a-preseason-1-000-bet-on-nikola-jokic-to-win-nba-mvp-paid-out">won </a>the MVP with 91 first-place votes and 971 total weighted points.
What&rsquo;s Next: The Lakers will likely be among the top favorites for the 2021-2022 NBA season. James could be determined to have a bounce-back season after getting knocked out early in the NBA Playoffs and getting only one vote in the MVP race.
Photo by&nbsp;<a href="https://unsplash.com/@chichi1813?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Chichi Onyekanne</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/lebron?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

LeBron James Switching Jersey Number From 23 To 6: Here's Which Jersey James Helps Bettors In More

<ul>
<li>The cover story in this weekend&#39;s <a href="http://www.benzinga.com/topic/barron-s">Barron&#39;s</a> examines how teenage traders are shaking up the market.</li>
<li>Other featured articles discuss which drugmakers benefit from a new market, why it is time to buy momentum stocks and how to safely hunt for yield.</li>
<li>Also, see the prospects for a semiconductor and a shipping giant, solar stocks, meme stocks and more.</li>
</ul>
&quot;<a href="https://www.barrons.com/articles/teen-traders-shaking-up-the-stock-market-51623444382">Here Come the Teens: They Can&#39;t Vote, but They&#39;re Old Enough to Buy Stocks</a>&quot; by Daren Fonda points out that young traders are shaking up the market, as new apps make it easy and brokerage firms eagerly court them. Find out whether Barron&#39;s believes that this is good news for the likes of Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) andTesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>).
Reshma Kapadia&#39;s &quot;<a href="https://www.barrons.com/articles/taiwan-semi-stock-51623366589">How to Play the World&#39;s Most Vital Chip Maker</a>&quot; makes a case that Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) has never been more important, as this critical supplier to U.S. and Chinese technology giants sits at the nexus of a global chip renaissance. At the same time, says the article, there are near-term risks for the company and its rather pricey stock.
In &quot;<a href="https://www.barrons.com/articles/income-yield-ladder-51623420002">Go On, Climb the Yield Ladder. Here&#39;s How to Do So Safely</a>,&quot; Alexanda Scaggs discusses why, for investors sick of fixed-income investments that pay almost no interest, there is an alphabet soup of solid yields to be had for those willing to ratchet up the risk. Among the many options mentioned in the article are Ares Capital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amc#NASDAQ">AMC</a>) and PennyMac Mortgage Investment Trust (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pmt#NYSE">PMT</a>).
An enormous market that had eluded drug companies for decades was unlocked when the FDA approved an Alzheimer&#39;s disease therapy from Biogen Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>). So says to &quot;<a href="https://www.barrons.com/articles/biogen-alzheimers-drug-51623441976" target="_blank">Biogen&#39;s Alzheimer&#39;s Drug Opens Up a New Market. These Stocks Could Benefit</a>&quot; by Josh Nathan-Kazis. See why Barron&#39;s thinks the outlook looks bright for Eli Lilly And Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and others.
In Jack Hough&#39;s &quot;<a href="https://www.barrons.com/articles/solar-stocks-51623449939" target="_blank">Home Solar Is Cheap. The Stocks Have Soared. Buy Both</a>,&quot; discover why Barron&#39;s claims that &quot;tree-hugging now beats junk bonds.&quot; First Solar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flsr#NASDAQ">FLSR</a>) NextEra Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nee#NYSE">NEE</a>) and Sunrun Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/run#NASDAQ">RUN</a>) have surged in the past year, and the article suggests that the long-term economics look good.
&quot;<a href="https://www.barrons.com/articles/buy-momentum-stocks-51623454669" target="_blank">&#39;Momentum&#39; Stocks Are a Mess. Why It&#39;s Time to Buy Them Now</a>&quot; by Ben Levisohn states that the stock market&#39;s best-performing stocks have been anything but the best-performing stocks, though that may be about to change. Sound confusing? Things are made clear in the article, as is how Caterpillar Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cat#NYSE">CAT</a>), NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) and others fit in.
See also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21539701/benzingas-bulls-and-bears-of-the-week-apple-amazon-biogen-bitcoin-tesla-and-more">Benzinga&#39;s Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More</a>
United Parcel Service, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ups#NYSE">UPS</a>) stock is still a buy, according to Al Root&#39;s &quot;<a href="https://www.barrons.com/articles/ups-stock-got-dinged-this-week-heres-why-its-a-buy-now-51623456516" target="_blank">UPS Stock Got Dinged This Week. Here&#39;s Why It Could Rise 43%</a>,&quot; despite this past week&#39;s disappointing investor event. After all, the shipping giant and economic bellwether expects profit margins to expand over the coming three years, driving earnings growth of about 15% a year on average.
In &quot;<a href="https://www.barrons.com/articles/docusign-stock-meme-51623321001" target="_blank">Why DocuSign Stock Is a Smarter Meme Trade</a>,&quot; Steven M. Sears discusses how the Docusign Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/docu#NASDAQ">DOCU</a>) electronic signature technology may be replacing the old way of signing documents, but the share price is anemic compared with AMC Entertainment Holdings Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) or GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>).
Avi Salzman&#39;s &quot;<a href="https://www.barrons.com/articles/milking-the-newest-meme-stock-51623452156">Milking the Newest Meme Stock</a>&quot; explores why, beneath the jokes about cow poop and the positive thoughts about its business model, the Reddit posters seem to be seeing Clean Energy Fuels Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clne#NASDAQ">CLNE</a>) as another opportunity for a short squeeze. See where shares of this California-based natural gas producer may be headed next.

Media

CLNE

DOCU

FLSR

NVDA

The Latest Barron's Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More

On <a href="https://www.cnbc.com/video/2021/06/11/final-trades-skin-orcl-pfe-fsr.html">CNBC&#39;s &quot;Fast Money Final Trades,&quot;</a> James McDonald said he has a price target of $20 for Beauty Health Co (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skin#NASDAQ">SKIN</a>).
Victoria Fernandez is a buyer of Oracle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>). The catalyst for the stock is the cloud space going forward, she said.
Dan Nathan wants to buy Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>). He expects the stock to return to its all-time highs.
Steve Grasso said Fisker Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) caught a bid and it bounced aggressively. He expects it to continue to move higher.

ORCL

SKIN

'Fast Money' Picks For June 14

The Euro 2020 is set to begin June 11 with the Group Stage and run through July 11. The games will be aired on ESPN and EPSN+, both units of&nbsp;Walt Disney Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>).
Ahead of the quadrennial soccer tournament featuring the top teams in Europe, Benzinga is providing group betting previews. Group E Betting Odds from DraftKings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>) are:
<ul>
<li>Spain to win Group E at -265, to finish in top two -1250</li>
<li>Poland to win Group E at +575, to finish in top two -104</li>
<li>Sweden to win Group E at +650, to finish in top two +102</li>
<li>Slovakia to win Group E at +1900, to finish in top two +475</li>
</ul>
There are many betting options for soccer games including betting on the winner, a tie, a team to win or tie, over/under, correct score, both teams to score and the winning margin.
For this betting preview, we will be looking at who is likely to win Group E and finish second as the top two teams will advance past the group stage.
The biggest favorite to win their respective group is Spain (FIFA rank: 6). The team posted an 8-2-0 record with 31 goals scored and 5 goals allowed. The team had ties with Norway and Sweden in qualifying. Spain is a top pick to win the overall tournament and it should win Group E.
Poland (FIFA rank: 21) poses a small threat to Spain in the group. The team went an impressive 8-1-1 in the qualifying rounds and posted a goal differential of 13.
Sweden (FIFA rank: 18) comes in with a higher FIFA ranking than Poland but is predicted to finish behind them in the group stage. Sweden went 6-3-1 in qualifying with a loss and tie with Spain. Sweden has faced some strong competition since qualifying with matches against Croatia, France and Portugal.
One thing that sets up nicely for Sweden is its schedule. The team faces Spain first getting the big game out of the way and plays Poland with a match knowing exactly what it needs to advance.
Slovakia (FIFA rank: 36) is the odd man out in the group and will struggle to advance. The team finished with a 4-1-3 record in qualifying.
Group E Picks: There isn&rsquo;t a ton of value in betting Spain to win the group unless combined with another group winner.
The value in the group is picking between Poland and Sweden to finish second. Poland had the better qualifying record but Sweden seems battle-tested recently and has the more favorable schedule, which could lead to Sweden finishing second.
(Photo by <a href="https://unsplash.com/@introspectivedsgn?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Erik Mclean</a> on <a href="https://unsplash.com/s/photos/soccer-ball?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>)

Euro 2020 Group E Betting Preview And Picks

Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk has ruffled enough feathers with his fervent tweets on cryptocurrency that a group has launched a whole new project aimed simply at putting an end to his alleged market manipulation. Benzinga talked to the people behind StopElon (STOPELON) on their ambitious plans to oust Musk as the CEO of Tesla and &quot;rid the world of cryptocurrency manipulation.&quot;
Simple Visceral Emotion: &ldquo;We are simply cryptocurrency investors who saw significant losses in our portfolio the day Elon Musk stated that Tesla is not <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21096462/breaking-tesla-suspends-vehicle-purchases-via-bitcoin-over-environmental-concerns" style="text-decoration-line:none">accepting Bitcoin as payment</a>,&rdquo; Daniel, the co-founder of StopElon, told Benzinga.&nbsp;
Daniel disclosed that the project was created &ldquo;from an initial burst of frustration&rdquo; but they had not imagined &ldquo;such a roadmap and ambitious goals from the beginning.&rdquo;
StopElon &ldquo;has been built from a simple visceral emotion into a real movement to fight against market manipulation.&rdquo;
StopElon traded 17.5% lower at $0.00001734 at press time on Sunday, as per CoinGecko data. The top market for the coin is PancakeSwap (v2).
Why Target Musk Particularly? Cryptocurrency markets can crash for a variety of reasons. In the recent past they have fallen after Chinese regulators <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21205311/bitcoin-crashes-below-32-000-takes-tesla-coinbase-microstrategy-and-other-cryptos-down-wit">announced measures</a> to restrict mining and a slew of other negative news, so why pick on Musk alone?
&ldquo;We&rsquo;re focused on Elon Musk because he is apparently flip-flopping on his position and [reveling] in the price impacts he&rsquo;s having as if it is a joke,&rdquo; said the StopElon spokesperson.
The project illustrated their point with Musk propelling Dogecoin (DOGE) to the fifth spot among cryptocurrencies and then calling it <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21026043/heres-the-elon-musk-dogecoin-bit-on-snl-everyone-is-talking-about" style="text-decoration-line:none">a &ldquo;hustle&rdquo; on television</a>.&nbsp;
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/" style="text-decoration-line:none">How to Buy Dogecoin (DOGE)</a>
&ldquo;This is clear manipulation for amusement&rsquo;s sake, not price impact from real changing market conditions.&rdquo;
The group also pointed to Tesla selling <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/" style="text-decoration-line:none">Bitcoin</a> (BTC) <a href="https://www.benzinga.com/markets/cryptocurrency/21/04/20804360/tesla-sold-272m-bitcoin-in-q1-musk-responds-to-portnoys-allegations-of-pump-and-dump" style="text-decoration-line:none">$272 million worth of Bitcoin</a> in the first quarter as a second example of &ldquo;manipulation.&rdquo;&nbsp;
The StopElon spokesperson said that the sale came just two weeks prior to Tesla withdrawing Bitcoin purchases for vehicles. &ldquo;It&rsquo;s important to note this contradictory behavior is all coming from a single individual.&rdquo;&nbsp;
It is important to note that Musk cited the &ldquo;rapidly increasing use of fossil fuels&rdquo; for Bitcoin mining and transactions on Twitter as a reason for Tesla&rsquo;s stopping payments in the apex cryptocurrency.
Et Tu, Musk? &ldquo;There&rsquo;s a very real feeling of betrayal with Elon Musk,&rdquo; Daniel told Benzinga.&nbsp;
&ldquo;A lot of people entered the space because of him posting rockets and moons related to crypto. He suddenly changed sides which caused a lot of people who idolized him pain.&rdquo;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/03/20290599/is-elon-musks-influence-on-dogecoin-price-waning" style="text-decoration-line:none">Is Elon Musk&#39;s Influence On Dogecoin Price Waning?</a>
&ldquo;Despite this he continues to laugh at crashing prices and people&rsquo;s suffering as if it is a joke,&rdquo; lamented the co-founder of the project.
Is the anger towards Musk justified? Dogecoin co-creator Billy Markus explained it as&nbsp;people&#39;s tendency&nbsp;&quot;to get very emotional when crypto investing and it is very volatile.&rdquo;
Markus told Benzinga that &ldquo;people who own crypto tend to get excited about it and want to talk about it, regular or celebrity investors.&rdquo;
A Dose Of Regulation Perhaps? If cryptocurrencies are being manipulated, why not turn to the watchdogs? StopElon told Benzinga that global regulatory oversight will (not?)&nbsp;stop market manipulation.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21444772/stopelon-group-protests-elon-musks-cryptocurrency-market-manipulation-outside-tesla-fremon" style="text-decoration-line:none">&#39;Stopelon&#39; Group Protests Elon Musk&#39;s Cryptocurrency &#39;Market Manipulation&#39; Outside Tesla Fremont Factory</a>
&ldquo;It&rsquo;s difficult to eliminate manipulation through regulation in any case as the stock market has shown.&rdquo;
Stockpiling For Success: &ldquo;The first and most important item is establishing an ongoing voting trust,&rdquo; said Daniel. The project is discussing and designing this framework with its legal team.
&ldquo;Once complete it is our hope that anyone can &#39;stake&#39; their share&rsquo;s voting power with our project. This should allow anyone who owns shares of Tesla to give us the voting rights without us needing to worry about the tax and custodial issues of share ownership.&rdquo;
Another approach that compliments the first strategy is to use the project&rsquo;s marketing wallet to purchase several shares of the automaker and add them to the trust.
The project reckons they would need a neutral third party to act as a custodian of shares to address concerns such as where shares are held and who owns them, taxes, gains and what happens to the proceeds once shares are sold among others.
The project said it is not yet ready to announce the &ldquo;precise structure or timeline&rdquo; of its share purchases and staking. &ldquo;So this is speculative, but states our intended goal,&rdquo; as per the StopElon co-founder.
The Clock Is Ticking: So how long will it take for StopElon to achieve its goals? Benzinga inquired about the sense of urgency to stop the new <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21291823/elon-musk-the-next-bad-boy-of-crypto-at-least-incumbent-justin-sun-thinks-so" style="text-decoration-line:none">&ldquo;bad boy of crypto.&rdquo;</a>
&ldquo;We&rsquo;re looking at the long term here, and there&rsquo;s no reason to believe that our ambitions will be irrelevant by the time we achieve them,&rdquo; said Daniel.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21445126/weloveyouelon-trends-on-us-twitter-as-elon-musk-dogecoin-fans-look-to-counter-bitcoin-crit">&#39;WeLoveYouElon&#39; Trends On US Twitter As Elon Musk Dogecoin Fans Look To Counter Bitcoin Critics</a>
StopElon said that since cryptocurrency and blockchain technologies are still in early phases, they believe they are here to stay and they would &ldquo;more relevant than ever&rdquo; by the time it achieves critical mass or enough shares to oust Musk or stop his tweets.
Musk, Pluto, or Bust: So the people at StopElon have set high goals. One aim is to take over 2/3 of Tesla&rsquo;s shares and another is flying to Pluto.
&ldquo;This is incredibly ambitious, but it is absolutely possible,&rdquo; said the project&rsquo;s rep.&nbsp;
Who better to draw inspiration than from their b&ecirc;te noire. Quoting Musk who said, &ldquo;the most entertaining outcome is often the most likely,&rdquo; the spokesperson said, &ldquo;What could be more entertaining than an originally meme focused protest token literally taking over one of the most forward-thinking energy companies on the planet?&rdquo;
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21504329/exclusive-dogecoin-co-creator-on-development-efforts-says-no-knock-on-elon-others-but-acti">Dogecoin Co-Creator On Development Efforts Says &#39;No Knock On Elon,&#39; Others But Actions Speak Louder Than Words</a>
Photo by <a href="https://www.flickr.com/photos/163370954@N08/46339127625">Daniel Oberhaus</a> on Flickr

Government

$BTC

$DOGE

EXCLUSIVE: 'Clear Manipulation For Amusement's Sake,' Crypto Group Trying To Oust Elon Musk As Tesla CEO Says There's Sense Of 'Betrayal'

Biomea Fusion Shares Open For Trade At $20; IPO Priced At $17/Share

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 20)

<ul>
	<li>Alexion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALXN#NASDAQ">ALXN</a>)</li>
	<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="/stock/ATRC#NASDAQ">ATRC</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>)</li>
	<li>China Biologic Products Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/CBPO#NASDAQ">CBPO</a>) (announced completion of going private transaction)</li>
	<li>Dicerna Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/DRNA#NASDAQ">DRNA</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="/stock/IART#NASDAQ">IART</a>)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="/stock/UTHR#NASDAQ">UTHR</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="/stock/WST#NYSE">WST</a>)</li>
	<li>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="/stock/ZBH#NYSE">ZBH</a>) (reacted to FDA 510(k) clearance of the Rosa Partial Knee System for robotically-assisted partial knee replacement surgeries)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 20)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ADC Therapeutics SA (NYSE:<a class="ticker" href="/stock/ADCT#NYSE">ADCT</a>)</li>
	<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="/stock/ADMA#NASDAQ">ADMA</a>)</li>
	<li>Agile Therapeutics, Inc. (AGRX)</li>
	<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/AKYA#NASDAQ">AKYA</a>) (IPOed Friday)</li>
	<li>Allena Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALNA#NASDAQ">ALNA</a>)</li>
	<li>Angion Biomedica Corp. (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>)</li>
	<li>Applied Genetic Technologies Corporation (NASDAQ:<a class="ticker" href="/stock/AGTC#NASDAQ">AGTC</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Aurinia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/AUPH#NASDAQ">AUPH</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="/stock/BMEA#NASDAQ">BMEA</a>) (IPOed Friday)</li>
	<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="/stock/BMRA#NASDAQ">BMRA</a>)</li>
	<li>Brainstorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/BCLI#NASDAQ">BCLI</a>)</li>
	<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="/stock/BCTX#NASDAQ">BCTX</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="/stock/CCXI#NASDAQ">CCXI</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASDAQ:<a class="ticker" href="/stock/CFRX#NASDAQ">CFRX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) (Sell-side began initiating coverage following IPO quiet period expiry)</li>
	<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="/stock/EBS#NYSE">EBS</a>)</li>
	<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ENVB#NASDAQ">ENVB</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FNCH#NASDAQ">FNCH</a>)</li>
	<li>Foghorn Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/FHTX#NASDAQ">FHTX</a>)</li>
	<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GRTX#NASDAQ">GRTX</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Homology Medicines, Inc. (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/INM#NASDAQ">INM</a>)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>NuCana plc (NASDAQ:<a class="ticker" href="/stock/NCNA#NASDAQ">NCNA</a>)</li>
	<li>OraSure Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/OSUR#NASDAQ">OSUR</a>)</li>
	<li>Pharvaris B.V. (NASDAQ:<a class="ticker" href="/stock/PHVS#NASDAQ">PHVS</a>)</li>
	<li>Pulmatrix, Inc. PULM)</li>
	<li>Sigilon Therapeutics, Inc (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Stealth BioTherapeutics Corp (NASDAQ:<a class="ticker" href="/stock/MITO#NASDAQ">MITO</a>)</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>)</li>
	<li>Vaxcyte Inc (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>)</li>
	<li>Viveve Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/VIVE#NASDAQ">VIVE</a>)</li>
	<li>Vyne Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/VYNE#NASDAQ">VYNE</a>)</li>
	<li>Zymeworks Inc. (NYSE:<a class="ticker" href="/stock/ZYME#NYSE">ZYME</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Lilly Announces Presentation of Positive Phase 1/2 Study of Selpercatinib In RET fusion-positive Solid Tumors</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) announced that it presented at the 2021 American Association for Cancer Research Annual Meeting data from the Phase 1/2 trial showing treatment with selpercatinib demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies.

The company noted a confirmed objective response rate of 47%, with responses observed in nine unique cancer types. Median duration of response was not reached at 13 months, with 11 of 15 responses ongoing, it added. The company also said safety was consistent with the known profile of selpercatinib.

<h3>Moderna Strikes Deal to Supply Israel Variant-specific COVID Vaccine In 2022</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) announced a new supply agreement, with Israel, under which Israel also retains an option to purchase doses of one of Moderna&#39;s variant-specific vaccine candidates in 2022, subject to regulatory approval.

This follows two earlier agreements between Israel and Moderna to supply a total of 10 million doses of the COVID-19 Vaccine. The Israeli Ministry of Health authorized COVID-19 Vaccine Moderna for use on Jan.&nbsp;4.

<h3>Lumos Announces Retirement of CFO, Names Insider to the Role</h3>

Lumos Pharma, Inc. (NASDAQ:<a class="ticker" href="/stock/LUMO#NASDAQ">LUMO</a>) said chief financial officer Carl Langren, who has been with the company for 40 years, has announced his plans to retire effective as of July 4. Langren has been serving in the current role since November&nbsp;2019.

Lori Lawley, currently SVP, Finance and Corporate Controller, will succeed Langren as CFO. The company also announced the appointment of Eddie Varnado as VP, Finance and Corporate Controller.

<h3>Evelo Presents Positive Data for Phase 1b Study of Atopic Dermatitis Drug</h3>

Evelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVLO#NASDAQ">EVLO</a>) presented full clinical data from the Phase 1b clinical trial cohort evaluating EDP1815 for the treatment of mild and moderate atopic dermatitis in a poster presentation at the International Society of Atopic Dermatitis. The full results reinforce the data released on January 20, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes, the company said.

The stock was up 1.48% at $11 in after-hours trading.

<h3>Trevena Says Its Investigational Asset Included In Global Study For COVID-19 Treatment</h3>

Trevena, Inc. (NASDAQ:<a class="ticker" href="/stock/TRVNA#NASDAQ">TRVNA</a>) said its TRV027 has been selected for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients.

The stock was up 4.71% to $1.78 in premarket trading Wednesday.

<h3>Humanigen Announces Pharma Industry Veteran Adrian Kilcoyne as Chief Medical Officer </h3>

Humanigen, Inc. (NASDAQ:<a class="ticker" href="/stock/HGEN#NASDAQ">HGEN</a>), which is evaluating its lead drug lenzilumab for cytokine storm associated with COVID-19, said it has appointed Adrian Kilcoyne to the newly-created role of chief medical officer, effective immediately, reporting to Cameron Durrant, CEO of Humanigen.

He recently served as VP of Oncology Global Medical Affairs, Head of Evidence Generation and External Alliances, at AstraZeneca plc. (NASDAQ:<a class="ticker" href="/stock/AZN#NASDAQ">AZN</a>).

In premarket trading Wednesday, <a href="https://www.benzinga.com/general/biotech/21/03/20390403/humanigen-rallies-54-a-technical-analysis"> Humanigen shares </a> gained 1.18% to $13.70.

<h3>Applied DNA Pre-announces Above-consensus Q2 Revenues </h3>

Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/APDN#NASDAQ">APDN</a>) announced preliminary estimated second-quarter revenues in the range of $2.5 million to $2.7 million, up from $1.6 million in the first quarter and $552,000 in the year-ago quarter. Analysts, on average, estimate, revenues of $2.41 million.

The company attributed the sequential growth, principally to demand for safeCircle, its pooled COVID-19 surveillance testing program, and from sales of its Linea COVID-19 Assay Kit.

The company also said it&#39;s currently debt free.

<h3>Earnings </h3>

Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) said its first-quarter revenues climbed 18% year-over-year to $1.29 billion, and the non-GAAP net income per share climbed from $2.70 to $3.52, ahead of the $2.63 per share consensus.

The stock rose 3.81% to $842.02 in after-hours trading.

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) reported group sales of 14.93 billion francs ($16.26 billion) for the first quarter, down 1% but up 3% on a constant exchange rate. Sales of its Pharmaceutical business declined in all geographies, and the weakness was offset by a 50% increase in sales of its <a href="https://www.benzinga.com/general/biotech/21/03/20160023/roche-boosts-diagnostics-portfolio-with-1-8b-bet-on-covid-19-test-manufacturer-genmark">diagnostics business. </a> The company confirmed its outlook for 2021.

Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) said its first-quarter sales climbed 8% to $1.2 billion and EPS came in at 54 cents, exceeding the 47-cent per-share consensus estimate. The company raised its adjusted EPS guidance for 2021.

The stock added 3.76% to $93 in after-hours trading.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Guidance

Pre-Market Outlook

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

Piper Sandler analyst Joseph Catanzaro initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Overweight rating and announces Price Target of $27.

Price Target

Initiation

Analyst Ratings

Piper Sandler Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $27

JP Morgan analyst Gavin Scott initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Overweight rating and announces Price Target of $26.

JP Morgan Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $26

Jefferies analyst Eun Yang initiates coverage on Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy rating and announces Price Target of $26.

Jefferies Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $26

Upgrades

Downgrades

Intraday Update

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021

Offerings

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) reported quarterly losses of $(0.49) per share. This is a 880 percent decrease over losses of $(0.05) per share from the same period last year.

Biomea Fusion Q1 EPS $(0.49) Down From $(0.05) YoY

ABCL

ACHL

ACHV

ADCT

ADMA

ADMS

AFIB

AGTC

AKBA

AKUS

AKYA

ALGS

ALNA

AMGN

ANGN

APDN

APLS

APPF

APRE

APTX

APYX

AQST

ARCT

ASMB

ATNX

ATRC

ATVI

AUPH

AVDL

AVEO

AVIR

AVRO

AVXL

AXDX

AXSM

BCEL

BCLI

BCTX

BDSI

BEAM

BEEM

BHVN

BIOC

BLFS

BLNK

BLPH

BMEA

BMRA

BNGO

BNTX

BPTH

BTAI

CALA

CAPR

CARA

CBPO

CCXI

CEVA

CFRX

CLLS

CLPT

CLSN

CMPI

CMPS

CNCE

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-03
REV		(EXPECTED)2021-08-03

Q1 2021		Est.		Actual		Surprise
EPS				-0.490
REV				0

Recent Quotes

Earnings

Analyst Ratings

Related Companies

Biomea Fusion Frequently Asked Questions

How do I buy Biomea Fusion (BMEA) stock?

Who are Biomea Fusion's (BMEA) competitors?

What is the target price for Biomea Fusion (BMEA) stock?

Current Stock Price for Biomea Fusion (BMEA)?

Does Biomea Fusion (BMEA) pay a dividend?

When is Biomea Fusion (NASDAQ:BMEA) reporting earnings?

Is Biomea Fusion (BMEA) going to split?

What sector and industry does Biomea Fusion (BMEA) operate in?